2025 China Antibodies Contract Manufacturing Revenue Opportunities Report
Description
The 2025 China Antibodies Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in antibody contract manufacturing in China are WuXi Biologics, Asymchem, Shanghai Pharma Industrial, and MabPlex. WuXi Biologics is a global leader with extensive capabilities, offering end-to-end antibody development and large-scale production, including antibody-drug conjugates (ADCs), with facilities in multiple countries. Asymchem is known for innovative antibody engineering and sustainable manufacturing, covering from discovery to commercial production stages in China. Shanghai Pharma Industrial focuses on custom antibody manufacturing and large-scale biologics production, serving primarily Asia-Pacific clients with global expansion plans. MabPlex, based in Yantai, specializes in ADCs with advanced integrated production facilities, reflecting China’s growth in sophisticated biologics manufacturing.
These companies leverage China's growing talent pool, cutting-edge technology, and government support to compete globally. WuXi Biologics, with over 30,000 liters of capacity, serves Western clients heavily engaged in oncology biologics and ADC development. Asymchem and Shanghai Pharma adopt cost-effective approaches to biosimilars and custom biologics, expanding China’s footprint in antibody manufacturing. MabPlex exemplifies a new generation of firms combining chemistry, cell culture, and conjugation expertise in integrated facilities. Together, they form a robust backbone of China’s antibody contract manufacturing sector, serving local and international pharmaceutical companies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in antibody contract manufacturing in China are WuXi Biologics, Asymchem, Shanghai Pharma Industrial, and MabPlex. WuXi Biologics is a global leader with extensive capabilities, offering end-to-end antibody development and large-scale production, including antibody-drug conjugates (ADCs), with facilities in multiple countries. Asymchem is known for innovative antibody engineering and sustainable manufacturing, covering from discovery to commercial production stages in China. Shanghai Pharma Industrial focuses on custom antibody manufacturing and large-scale biologics production, serving primarily Asia-Pacific clients with global expansion plans. MabPlex, based in Yantai, specializes in ADCs with advanced integrated production facilities, reflecting China’s growth in sophisticated biologics manufacturing.
These companies leverage China's growing talent pool, cutting-edge technology, and government support to compete globally. WuXi Biologics, with over 30,000 liters of capacity, serves Western clients heavily engaged in oncology biologics and ADC development. Asymchem and Shanghai Pharma adopt cost-effective approaches to biosimilars and custom biologics, expanding China’s footprint in antibody manufacturing. MabPlex exemplifies a new generation of firms combining chemistry, cell culture, and conjugation expertise in integrated facilities. Together, they form a robust backbone of China’s antibody contract manufacturing sector, serving local and international pharmaceutical companies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
